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Abstract
It is well established that in adults, long-term repopulating hematopoietic stem cells (HSC) are mitotically quiescent cells
that reside in specialized bone marrow (BM) niches that maintain the dormancy of HSC. Our laboratory demonstrated that
the engraftment potential of human HSC (CD34
+ cells) from BM and mobilized peripheral blood (MPB) is restricted to cells in
the G0 phase of cell cycle but that in the case of umbilical cord blood (UCB) -derived CD34
+ cells, cell cycle status is not a
determining factor in the ability of these cells to engraft and sustain hematopoiesis. We used this distinct in vivo behavior of
CD34
+ cells from these tissues to identify genes associated with the engraftment potential of human HSC. CD34
+ cells from
BM, MPB, and UCB were fractionated into G0 and G1 phases of cell cycle and subjected in parallel to microarray and
proteomic analyses. A total of 484 target genes were identified to be associated with engraftment potential of HSC. System
biology modeling indicated that the top four signaling pathways associated with these genes are Integrin signaling, p53
signaling, cytotoxic T lymphocyte-mediated apoptosis, and Myc mediated apoptosis signaling. Our data suggest that a
continuum of functions of hematopoietic cells directly associated with cell cycle progression may play a major role in
governing the engraftment potential of stem cells. While proteomic analysis identified a total of 646 proteins in analyzed
samples, a very limited overlap between genomic and proteomic data was observed. These data provide a new insight into
the genetic control of engraftment of human HSC from distinct tissues and suggest that mitotic quiescence may not be the
requisite characteristic of engrafting stem cells, but instead may be the physiologic status conducive to the expression of
genetic elements favoring engraftment.
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Introduction
Life-long maintenance of the hematopoietic system is sustained
by highly specialized hematopoietic stem cells (HSC) [1,2,3]. In
steady state, HSC are highly dormant undergoing self-renewal
divisions rather infrequently. However, the molecular mechanisms
governing their mitotic quiescence are largely unknown. During
mammalian development, stem cells first appear in the yolk sac,
then migrate into the fetal liver, and finally migrate into bone
marrow (BM). We previously completed [4,5,6] a survey of the
potential of cycling and non-cycling HSC from human hemato-
poietic tissues through ontogeny to engraft in conditioned NOD/
SCID recipients. When human mobilized peripheral blood (MPB)
and BM CD34
+ cells in G0 or G1 phase of cell cycle were
examined, only those in G0 were capable of in-vivo long-term
multilineage engraftment [4]. In contrast, both mitotically
quiescent as well as cycling HSC from umbilical cord blood
(UCB), fetal liver and human fetal bone marrow [5,6] retained
their ability to engraft in NOD/SCID mice. Collectively, these
studies established that in adult tissues, a hierarchical order of
hematopoietic potential can be assembled based on the mitotic
status of HSC whereby only cells in G0 engraft. On the other
hand, in the case of prenatal HSC (including UCB) such a
hierarchy does not predominate and both cycling (cells in G1) and
quiescent (cells in G0) cells retain their hematopoietic potential. It
is therefore possible that genes mediating in vivo stem cell
engraftment function may be differentially expressed in adult
BM and MPB CD34
+G0 cells, and UCB CD34
+G0 and G1 cells,
but not in adult MPB and BM CD34
+ cells in G1. Alternatively,
one has to consider that if any of the continuum models of stem
cell function that have been proposed [7,8,9,10] is operative, then
a change in gene expression between cells in G0 versus those in
G1, that may control the ability of cells to engraft, should still be
detectable even if all cell cycle regulation genes were eliminated
from further analysis. The availability of six groups of human
CD34
+ cells from three distinct tissues with previously established
functional capabilities allowed us to carefully investigate the
genetic control of pathways implicated in engraftment and to
examine the degree of homogeneity or heterogeneity between
functionally similar (all G0 groups of cells and G1 cells from UCB)
but phenotypically different (G0 and G1 cells from UCB) groups of
cells in the absence of the impact of cell cycle regulatory genes.
Although microarrays are informative in their ability to measure
biological differences at the mRNA level [11], most functional
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more relevant parameter for the assessment of operational
mechanisms [12]. Recent advances in analyzing global protein
expression profiles and in label-free quantification have demon-
strated the potential for comparative proteomic studies. Although
several studies demonstrated the presence of moderate to poor
correlations between microarray and proteomic analyses
[13,14,15,16], implementing both methods may generate com-
plementary and more informative data that cannot be obtained by
either method alone. Recently, microarray and proteomic analyses
of human and mouse stem cells generated insights into the
molecular composition of stem cell profiles [17,18,19,20,21,22,
23,24,25]. In the present study, we investigated the global gene
and protein expression profiles of G0 and G1 cells from human
BM, MPB, and UCB-derived CD34
+ cells by whole genome
microarrays and mass spectrometry based proteomic techniques,
respectively. Our data provide a unique comparative evaluation of
the genomic and proteomic profiles of well-characterized groups of
human HSC and illustrate that these analyses may not necessarily
generate complementary or compatible results. Furthermore, our
data suggest that gene expression patterns in HSC may oscillate in
a cell cycle related manner to confer engraftment potential on cells
in one or more phases of cell cycle depending on the develop-
mental stage and need for functional HSC.
Materials and Methods
Human CD34
+ cells
BM and UCB samples were ficolled and mononuclear cells were
collected followed by CD34
+ selection using Miltenyi Magnetically
Activated Cell Sorting (MACS) columns according to the
manufacturer’s directions (Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany). Mobilization was achieved by daily granu-
locyte colony-stimulating factor administration at 5 mg/kg (max-
imum of 480 mg/day) for 4 consecutive days. Apheresis was
performed on day 5 and CD34
+ cells were isolated by immuno-
magnetic selection on an Isolex 300i system (Nexell, Irvine, CA). To
generate distinct and unique sets of data, we did not pool multiple
samples from any tissue studied so that each sample or its replicate
was from a single donor. Purity of selected CD34
+ fractions was
assessed by flow-cytometric analysis with an antibody recognizing a
different CD34 epitope (BD Biosciences, San Jose, CA). The
efficiency of the MACS columns was over 80% and the efficiency of
theIsolex300isystemexceeded95%.AllsamplesofselectedCD34
+
cells were cryopreserved prior to their use.
Ethics Statement
All studies described in this manuscript were approved by the
Investigational Review Board of Indiana University School of
Medicine. BM and MPB samples were collected from healthy
adult volunteers after obtaining a written and signed informed
consent according to the guidelines of our institutional IRB.
Cell-cycle fractionation with Hoechst 33342 (Hst) and
Pyronin Y (PY)
To distinguish cells in G0 or G1, which have the same DNA but
different RNA content, simultaneous DNA/RNA staining with
Hoechst 33342 (Molecular Probes, Eugene, OR) and Pyronin Y
(Polysciences, Warrington, PA), respectively, was performed as
previously described [26,27]. At the end of the staining with Hst
and PY, cells were washed once in ice-cold Hst buffer and
incubated for 30 minutes with APC–conjugated CD34 at 4uC.
Cells were washed again, resuspended in Hst buffer, and analyzed
or sorted on FACS Aria (BDIS). Cells in G0 (G0CD34
+) were
identified by their 2n DNA and minimal RNA content; cells in G1
(G1CD34
+) were defined as those with 2n DNA and high RNA
staining [28]. Cell sorting criteria were identical to those
previously described [4] allowing us to separate the upper limit
of the G0 sort window from the lower limit of the G1 sort window
by at least 150 fluorescence channels. Viability of sorted cells
always exceeded 98%. A representative dot plot is shown in
Figure 1A and 1B. From each sort window, two separate aliquots
of 10
4 and 2610
5 cells were sorted for genomic and proteomic
analyses, respectively.
Quantitative Real-Time PCR
To confirm the cell cycle status of sorted G0CD34
+ and
G1CD34
+ cells, their relative expression of Ki67 was measured by
qRT-PCR. cDNA was made on mMACS columns (Miltenyi Biotec,
Auburn, CA) using mMACS one-step cDNA kit (Miltenyi Biotec,
Cat # 130-091-902) following the manufacturer’s instructions.
qRT-PCR was performed using Taqman probe following the
manufacturer’s instructions (Applied Biosystems, Foster City, CA).
PCR amplification wasperformed ina 20-mlfinal volumecontaining
10 ml2 6 Taqman universal PCR master mix, 1 mlo f2 0 6 Ki67
assay mix, 9 ml template (cDNA diluted) at 50uCf o r2m i n ,9 5 uCf o r
10 min, followed by 40 cycles at 95uC for 15 sec and 60uCf o r
1 min. Expression of GAPDH was used for normalization. Cells
were acceptable for further analysis if the relative expression of Ki67
among G0CD34
+ cells was 90–95% lower than that detected in
G1CD34
+ cells from all 3 tissues (Figure 1C).
Microarray analysis
Triplicate samples of G0 and G1 cells from BM, MPB, and
UCB (total of eighteen samples) were lysed in Miltenyi Super Amp
lysis buffer and the downstream microarray analysis was carried
out by Miltenyi Biotec. Briefly, mRNA was made using magnetic
bead technology followed by cDNA preparation and amplifica-
tion. cDNA samples were quantified using an ND-1000 Spectro-
photometer (NanoDrop Technologies) and cDNA integrity was
checked via the Agilent 2100 Bioanalyzer platform. 250 ng of the
cDNA were labeled with Cy3 and hybridized overnight (17 hours,
65uC) to an Agilent Whole Human Genome Oligo Microarrays.
Finally, the microarrays were washed and fluorescence signals of
the hybridized Agilent Microarrays were detected using Agilent’s
Microarray Scanner System. The Agilent Feature Extraction
Software (FES) was used to read out and process the microarray
image files. For determination of differential gene expression, FES
derived output data files were analyzed using the Rosetta Resolver
gene expression data analysis system (Rosetta Biosoftware). Signal
intensities from the single-experiment raw data lists were
normalized by dividing the intensity values by their median.
Standard deviation and p-values were calculated for each probe.
Differentially expressed genes with at least two-fold change and p-
value,0.01 were considered for further analysis. Gene clustering
analysis was done using TM4 MultiExperiment Viewer (version
4.3) [29]. The metadata and raw data files of microarray
experiments (all MIAME compliant) were deposited in a MIAME
compliant database, Gene Expression Omnibus (Accession
numbers GSM595960 to GSM595977, a total of 18 samples).
Protein extraction and sample preparation for Proteomic
analysis
Samples for mass spectrometry were prepared as previously
described [30]. Briefly, 3 to 5 biological replicates of G0 and G1
cells from BM, MPB, and UCB were homogenized in hypotonic
lysis buffer containing freshly made 8 M urea and 10 mM DTT
Genomic & Proteomic Analysis of Human CD34
+ Cells
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17498solution. Proteins were reduced with 20 mL of 200 mM DTT in
100 mM Tris-Cl (pH 7.8) for 1 h at room temperature, alkylated
with 20 mL of 200 mM iodoacetamide in 100 mM Tris-Cl
(pH 7.8) in the dark for 1 h, and diluted to a final urea
concentration of 0.6 M, a concentration at which trypsin retains
its activity. Trypsin solution was added to a final ratio of enzyme to
substrate of 1:50. Digestion was carried out at 37uC and stopped
15 h later by adding 10 mL of 10 mM lysine. pH was then
adjusted to below 6.0 and vacuum dried to a final volume of
25 mL. Peptide concentration was determined by the Bradford
protein assay [31]. Peptide mixtures were subjected to LC/MS.
Mass spectrometry and protein quantification
Mass spectrometry analysis was carried out as previously
described [30]. Briefly, using a Surveyor HPLC system
(Thermo-Finnigan), all tryptic peptides were injected onto a C18
microbore column (Zorbax 300SB-C18) in a random order.
Peptides were eluted from the column by acetonitrile linear
gradient from 5 to 45 developed over 120 min at a flow rate of
50 mL/min. Eluted peptides were directly electro-sprayed into an
LTQ mass spectrometer (Thermo-Finnigan). Data were collected
in the ‘‘Triple-Play’’ mode and acquired data were filtered and
analyzed by a proprietary algorithm developed and described by
Higgs et al [32]. Using X!Tandem and SEQUEST algorithms, we
searched the database against the International Protein Index (IPI)
human database and the nonredundant-homo sapiens database.
Protein quantification and differential expression of proteins were
done using a proprietary software licensed from Eli Lilly and
Company [32].
Gene Ontology and Pathway analysis
Candidate genes or proteins were analyzed for their gene
ontology and pathway analysis using the Database for Annotation,
Visualization and Integrated Discovery (DAVID), sixth version,
the web based program [33,34] and Pathways Analysis software
7.5 (IPA, Ingenuity Systems, Mountain View, California). The
provided list of genes was mapped to Ingenuity Pathways
Knowledgebase (IPKB) and the functional categorization and
Figure 1. A representative figure showing typical flow cytometric cell sorting of BM, MPB, or UCB CD34
+ cells into G0 and G1
phases of cell cycle. CD34
+ cells selected on a Miltenyi MACS column were stained with APC conjugated CD34 antibody, Hst and PY. (A): CD34
positive cells were gated and analyzed for Hst and PY. (B): Quiescent cells residing in G0 phase have 2n DNA and minimal RNA content, whereas
those in early or late G1 phase are PY bright owing to their higher RNA content. According to this definition, G0 and G1 cells were sorted based on
their relative Hst and PY intensities. At least 150 fluorescence channels separated the 2 sort windows. (C): In order to confirm the purity of sorted cells,
post sort analysis was carried out by measuring the relative expression of a cell cycle marker, Ki67 by qRT-PCR. About 10,000 cells from each sorted
group were analyzed by qRT-PCR using a TaqMan probe and ABI 7800 real time PCR machine.
doi:10.1371/journal.pone.0017498.g001
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Fisher exact test was used to calculate P-values. P#0.05 was used
to select significant biological functions and pathways associated
with candidate genes.
Results
Differential gene expression profile of G0 and G1 cells
from BM, MPB, and UCB
To identify genes differentially expressed between quiescent
(G0) and cycling (G1) cells, we examined the global mRNA
expression profiles of sorted and qRT-PCR verified G0 and G1
cells from BM, MPB, and UCB. Among the analyzed 43,356 total
genes, 2685 genes were differentially expressed between G0 and
G1 cells from UCB. Of these, 1432 genes were upregulated in G0
cells whereas 1253 genes were upregulated in G1 cells (Rather
than using conventional terminology to describe these 1253 genes
as ‘‘downregulated’’ in G0, we will instead refer to these as
‘‘upregulated’’ in G1 throughout the manuscript). In case of MPB,
1705 genes were differentially expressed; 840 genes were
upregulated in G0 cells and 865 genes were upregulated in G1
cells. In contrast, BM derived CD34
+ cells were very dynamic
whereby 10,256 genes (23.6% of total genes), were differentially
expressed between G0 and G1 cells (4522 upregulated in G0 cells
and 5734 upregulated in G1 cells). Only 159 differentially
expressed genes between G0 and G1 cells were common for all
three tissues (Figure 2A).
Rationale for the identification of engraftment related
target genes
Differential engraftment of CD34
+ cells from different sources
gave us a unique opportunity to identify target genes responsible
for engraftment by eliminating differentially expressed genes
associated with the traverse of cells from G0 to G1. To proceed
with our analysis, we made three assumptions. First, in the case of
BM, since only G0 cells engrafted, we assumed that genes
responsible for engraftment were differentially expressed between
BM-G0 and BM-G1. Second, we assumed that since BM and
MPB are similar in terms of their engraftment profile, candidate
genes identified in BM should also be identified in MPB. On the
other hand, since both UCB G0 and G1 cells can engraft, genes
that are responsible for engraftment must be similarly (either up or
down) expressed between G0 and G1. Our third assumption was
that genes differentially expressed between UCB G0 and G1 are
primarily cell cycle related and are most likely not involved directly
with the engraftment potential of these cells. Therefore, we
hypothesized that candidate genes responsible for engraftment
may be identified by the subtraction of differentially expressed
genes between G0 and G1 of UCB from those that are
differentially expressed between G0 and G1 of BM and MPB.
To corroborate the third assumption, we phenotypically compared
markers of hematopoietic differentiation between UCB G0 and
G1 cells. As can be seen in Figure S1, the expression patterns of 10
hematopoietic markers were identical between UCB G0 and G1
cells demonstrating that the phenotypic makeup of these two
groups did not significantly impact the profiles obtained. For
added comparisons, we also analyzed BM G0 and G1 cells and
obtained the same profiles between both groups (Figure S1).
We identified 643 common differentially expressed genes
between both BM and MPB G0 and G1 cells and 159
differentially expressed genes between UCB G0 and G1 cells
were common with these 643 genes. Based on our proposed
model, we were left with 484 (6432159=484) target genes that
are most likely not cell cycle related but important for the control
of engraftment of HSC from all three tissues. This rationale is
depicted in Figure 2A and the list of the 484 target genes along
with their relative expression is shown in Table S1.
Cluster analysis
We carried out hierarchical cluster analysis of the target genes
using open source software TM4-MultipleExperiment Viewer
[29,35]. We chose default Euclidean distance metric and average
linkage clustering method to analyze the data. Out of 484 target
genes, 132 were upregulated in G0 cells of both in BM and MPB
(unchanged in UCB), 207 were upregulated in G1 cells of both
BM and MPB, and unchanged in UCB. The remaining 145 genes
showed aberrant expression patterns (Figure 2B). Therefore,
further gene ontology analysis was carried out on the 339
(132+207=339) genes that showed the same expression pattern
both in BM and MPB and remained unchanged in UCB.
Gene Ontology (GO) and Pathway analyses
Microarray identified target genes were further classified
following the GO rules based on: (i) the cellular component
(CC) indicating where the gene product can be found; (ii) the
biological process (BP) in which the gene product participates; (iii)
the molecular function (MF) that describes the gene product
activities. As shown in Table 1, the top molecular and cellular
functions associated with genes upregulated in engrafted cells were
cellular movement, antigen presentation, cell signaling, molecular
transport, and nucleic acid metabolism. Whereas, genes upregu-
lated in non engrafted cells were mostly associated with cellular
growth and proliferation, cell cycle, cellular assembly and
organization, and DNA replication. Interestingly, nine genes
(ADAMTS1, THBS1, TIMP3, PTGS1, NCKAP1, EVI1,
MFGE8, ITGA2, ENST00000353442, p=2.62E-04 - 3.80E-02)
with ‘‘embryonic development function’’ were also upregulated in
G0 cells of BM and MPB but relatively unchanged in G0 and G1
of UCB (Table 2). The top canonical pathways associated with
engrafted cells were: integrin signaling (e.g. DIRAS3, ITGA2,
TSPAN6), P53 signaling (e.g. GADD45A, THBS1), oncostatin M
signaling (e,g. TIMP3), T helper cell differentiation (e.g. IL18R1)
whereas the top canonical pathways associated with non-engrafted
cells were: Interleukin signaling (e.g. IL2, IL8, IL15), myc
mediated apoptosis signaling (e.g. IGF1, BCL2), and cytotoxic T
lymphocyte mediated apoptosis. Interestingly, several genes
upregulated in engrafted cells had an inverse function on genes
upregulated in non-engrafted cells and vice versa (Figure 3). These
inverse relationships will be discussed in some detail further below.
Comparison of target genes with other published data
We compared our present data to those previously reported by
Ivanova et al [25] in which a molecular signature of stem cells was
described. Among the 484 target genes identified in our studies,
the annotation and function of 341 genes are known. Compared to
published database [25], 57 of the 341 genes were identified as
common HSC specific genes (Table S2A). These 57 genes were
described among many of the categories of hematopoietic cells
described by Ivanova et al [25] with 26 of the 57 genes expressed
in the 3 categories of HSC, long term-HSC and short term-HSC.
Interestingly, our analysis identified 14 genes that Ivanova et al
[25] reported as genes expressed in stem cells from multiple tissues
including HSC, ESC and NSC (Table S2B).
Proteomic analysis
Mass spectrometry analyses of the same 6 groups of cells yielded
646 protein identities present in all samples. Based on the
Genomic & Proteomic Analysis of Human CD34
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PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17498Figure 2. Genomic analysis of human BM, CB, and MPB CD34+ cells in different phases of cell cycle. (A) Microarray analyses of G0CD34
+
and G1CD34
+ cells from BM, MPB, and UCB (3 replicates per group, total of 18 samples) were carried out using Agilent whole human genome oligo
chips. The signal intensities from the single-experiment raw data lists were normalized by dividing the intensity values by their median. Standard
deviation and p-values were calculated for each probe. The differentially expressed genes with at least two fold change and p-value,0.01 were
considered as differentially expressed genes. Among the 43,356 total analyzed genes, 10256, 1705, and 2685 genes were differentially expressed
between G0 and G1 cells of BM, MPB, and UCB, respectively. In order to identify target genes related to engraftment, common differentially expressed
genes between G0 and G1 from both BM and MPB were identified (643 genes). A total of 159 differentially genes between G0 and G1 cells of UCB
were common with these 643 genes. Considering that these 159 genes were related to progression of cells from G0 to G1 and therefore not involved
in engraftment, our analysis focused on the difference between these two sets of genes, namely, 484 genes (6432159=484). *=target genes. (B):
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priorities 1, 2, 3, or 4 based on the quality of protein identification
(see Table S3 for further details). The gene ontology analysis of
these proteins is shown in Table 3. The major cellular components
(corresponding number of identified proteins in brackets) were
membrane-bound organelle (269), nucleus (194), cytosol (74),
cytoskeleton (63), and mitochondrion (48). Biological processes
with the largest number of identified proteins were nucleic acid
metabolism (161), gene expression (154), development (114),
transport (97), and cell differentiation (72). This analysis revealed
proteins that do not represent the major pathways and cellular
compartments identified by microarray analysis.
Differential expression of proteins between G0 and G1
To gain insight into the mechanism of engraftment at the
protein level, we examined protein differential expression in G0
and G1 cells from all three tissues. Differential expression of
proteins was measured from the largest to the smallest protein
intensity between groups. A significant fold change was based on
controlling the false discovery rate (FDR) at less than 5. The
relative expression of all proteins with individual standard error
charts are shown in Table S4. When the threshold was set to 1.5,
25 proteins ranked in priorities 1 and 2 from BM were
differentially expressed between G0 and G1. For the same
ranking, 12 proteins from MPB, and 22 proteins from UCB were
differentially expressed between G0 and G1 cells. Table S5
displays the list of differentially expressed proteins along with their
annotation, the sequence used to identify the protein, and fold
change. There were only 7 differentially expressed proteins
common in all three tissues. To identify target proteins associated
with engraftment, analysis similar to that carried out for the
genomic data was performed. Using the same assumptions
discussed above, we identified 11 common proteins differentially
expressed by BM and MPB. Only 4 proteins however, were
commonly differentially expressed between BM and MPB, but not
UCB (Table S5).
Discussion
In adults, the quiescent status of HSC is believed to be a critical
determinant in the ability of these cells to retain their full
hematopoietic potential [36,37]. We previously hypothesized [6]
that in the developing fetus, and in order to meet the extensive
demand for the production of hematopoietic cells, all CD34
+ cells,
regardless of their position in the cell cycle, can sustain and
reinitiate blood cell production as hematopoiesis moves from one
site to the other during fetal development. Using a series of
transplantation studies [4,5,6] we demonstrated that only G0
CD34
+ cells from adult human BM or MPB engrafted successfully
in conditioned NOD/SCID mice and as predicted, both
G0CD34
+ and G1CD34
+ cells from UCB, fetal liver, and fetal
BM engrafted effectively [4,5,6]. While these studies revealed the
role of cell cycle status in the engraftment of CD34
+ cells during
ontogeny, the molecular basis behind these observations remains
Gene clustering analyses of 484 target genes were done using open source software TM4 MultiExperiment Viewer (version 4.3). Out of 484
differentially regulated genes, (i) 132 genes were upregulated in G0 cells of both BM and MPB (unchanged in UCB), and (ii) 207 genes were
upregulated in G1 cells of both BM and MPB (unchanged in UCB). The remaining genes displayed as aberrant expression patterns. (iii) 54 genes were
upregulated in BM G0 cells and MPB G1 cells, and (iv) 91 genes were upregulated in BM G1 and MPB G0 cells.
doi:10.1371/journal.pone.0017498.g002
Table 1.
(A): Top molecular and cellular functions of differentially upregulated genes in engrafted G0 cells.
Name p-value # Molecules
Cellular movement 6.90E-04 - 4.94E-02 12 CHN2, CXCL2, CXCL3, GADD45A, IL18R1, ITGA2,
NCKAP1, SHC4, SORT1, THBS1, TIMP3, TPM1
Antigen presentation 8.69E-04 - 4.02E-02 8 CXCL2, CXCL3, EVII, FCER1A, IL18R1, MFGE8, PTGS1, THBS1
Cell signaling 9.25E-04 - 4.50E-02 10 ABCC4, CXCL3, DIRAS3, FCER1A, GADD45A,
ITGA2, LPAR4, P2RY12, PTGS1, THBS1
Molecular transport 9.25E-04 - 4.94E-02 15 ABCC4, ARG2, CXCL3, DIRAS3, FCER1A, ITGA2,
LPAR4, P2RY12, PTGS1, RCRC1, SLC16A6,
SLC25A21, SLC40A1, SORT1, THBSI
Nucleic acid metabolism 9.25E-04 - 4.45E-02 6 ABCC4, CXCL3, ITGA2, LPAR4, P2RY12, THBS1
(B): Top molecular and cellular functions of differentially upregulated genes in non-engrafted G1 cells.
Name p-value # Molecules
Cellular growth and proliferation 3.68E-05 - 1.31E-02 18 AR, BCL2, BLM, DOCK4, ELF3, FANCD2, FGF13,
FYB, GNRHR, HAVCR2, HMMR, IGF1, IL2,
IRX3, MYCL1, SLC12A2, THBS2, TUBB3
Cell cycle 1.27E-04 - 1.31E-02 11 AR, BCL2, BLM, C11ORF82, CHAF1A, CHAF1B,
FANCD2, HAVCR2, IGF1, IL2, TOP2A,
Cellular assembly and organization 1.44E-04 - 1.31E-02 11 BCL2, BLM, CD48, CHF1A, CHF1B, CHL1,
IGF1, IL2, MTMR2, NEURL, THBS2
DNA replication, recombination,
and repair
1.44E-04 - 6.56E-03 8 AR, BLM, CHAF1A, CHAF1B,
IGF1, IL2, THBS2, TOP2A
Gene expression 2.50E-04 - 1.31E-02 7 AR, BCL2, ELF3, GNRHR, IGF1, IL2, SRCAP
doi:10.1371/journal.pone.0017498.t001
Genomic & Proteomic Analysis of Human CD34
+ Cells
PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17498unknown. Furthermore, these studies suggested that perhaps genes
differentially expressed between UCB G0CD34
+ and G1CD34
+
cells, especially those involved in cell cycle control may not be
critical for conferring engraftment capabilities. In this study, we
relied on previously published findings and the rational of
differential gene expression between G0CD34
+ and G1CD34
+
cells from different tissues to derive a genetic and protein
fingerprint that may be associated with the engraftment potential
of human stem cells and to examine whether our data can explain
the engraftment of cells in G0 based on their coordinated and
position in a continuum rather than a property that is strictly cell
cycle associated mitotically and genetically.
In our analysis, genes with at least two fold change and p-
value,0.01 were considered differentially expressed. Only 159
differentially expressed genes were common to all three tissues.
Regardless of engraftment potential, several genes undergo
differential expression when cells migrate from mitotic quiescence
(G0) to active phases of cell cycle (G1). Since we used CD34
+ cells
from 3 different tissues with distinct engraftment potential, we
were able to subtract genes that were differentially expressed
Table 2. Nine genes with ‘‘embryonic development function’’ that were upregulated in G0 cells.
Relative Expression G0/G1
GENE Gene Name UCB BM MPB
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif 1.78 5.2 9.18
THBS1 Thrombospondin 1 1.64 2.1 2.69
TIMP3 TIMP metallopeptidase inhibitor 3 1.34 2.78 2.16
PTGS1 Prostaglandin-endoperoxide synthase 1, transcript variant 1 1.39 5.6 4.53
NCKAP1 NCK-associated protein, transcript variant 2 1.0 2.67 4.38
EVI1 Ecotropic viral integration site 1 1.0 20.83 2.72
MFGE8 Milk fat globule-EGF factor 8 protein 1.79 3.0 2.1
ITGA2 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 1.5 17.76 4.12
ENST00000353442 Limb region 1 homolog (LMBR1) 1.68 3.6 2.58
doi:10.1371/journal.pone.0017498.t002
Table 3. Total identified proteins were grouped on the basis of cellular localization, biological process, and molecular function.
Cellular Component # % Biological process # % Molecular function # %
Membrane-bound organelle 269 50.6 Nucleic acid metabolic process 161 30.3 Protein binding 298 56
Nucleus 194 36.5 Gene expression 154 29 DNA binding 92 17.3
Cytosol 74 13.9 Protein metabolic process 138 25.9 RNA binding 89 16.7
Cytoskeleton 63 11.8 Cellular macromolecule
metabolic process
134 25.2 Structural molecule
activity
77 14.5
Mitochondrion 48 9 Developmental process 114 21.4 ATP binding 56 10.5
Chromosome 46 8.7 Transport 97 18.2 Oxidoreductase activity 42 7.9
Ribosome 42 7.9 Cell differentiation 72 13.5 Hydrolase activity 41 7.7
Chromatin 36 6.8 Macromolecule biosynthetic
process
64 12 Pyrophosphatase activity 41 7.7
Organelle envelope 31 5.8 DNA metabolic process 60 11.3 ATPase activity 23 4.3
Actin cytoskeleton 26 4.9 Translation 57 10.7 Unfolded protein binding 22 4.1
Nucleosome 24 4.5 RNA processing 43 8.1 Actin binding 22 4.1
Cytoplasmic vesicle 23 4.3 Programmed cell death 40 7.5 GTP binding 20 3.8
Spliceosome 21 4 Cell cycle 40 7.5 GTPase activity 16 3
Microtubule 13 2.4 Chromosome organization 39 7.3 Enzyme inhibitor activity 14 2.6
Cell surface 12 2.3 mRNA processing 34 6.4 Isomerase activity 12 2.3
Nuclear envelope 12 2.3 RNA splicing 32 6 Structural constituent
of cytoskeleton
12 2.3
Nucleolus 12 2.3 Chromatin assembly
or disassembly
30 5.6 Protein domain
specific binding
11 2.1
Contractile fiber 11 2.1 Anti-apoptosis 18 3.4 Lyase activity 11 2.1
Myosin complex 7 1.3 DNA repair 15 2.8 Antioxidant activity 10 1.9
Hetero Chromatin 5 0.9 Coenzyme metabolic process 15 2.8 Chromatin binding 8 1.5
doi:10.1371/journal.pone.0017498.t003
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related genes only. Nine genes, ADAMTS1, THBS1, TIMP3,
PTGS1, NCKAP1, EVI1, MFGE8, ITGA2, ENST00000353442,
with embryonic development function were upregulated in
engrafted cells. A number of these genes have an already identified
role in maintaining hematopoietic stem cells directly (EVI1) or
indirectly (ENST00000353442) by altering the expression of genes
implicated in the maintenance of stem cell function such as sonic
hedgehog [38]. Many of these genes play critical roles in
embryonic differentiation, implantation, and tissue homeostasis
(PTSG1) [39,40], in embryonic body morphogenesis and
gastrulation (NCKAP1) [41], and in organ morphogenesis
(ITGA2) [42] and limb patterning (ENST00000353442) [38].
How these genes collectively participate in controlling hemato-
poietic stem cell engraftment remains to be fully elucidated.
Interestingly, we found that the expression of several target
genes upregulated in engrafted cells can be inversely affected by
the expression of genes that were upregulated in non-engrafted
cells (Figure 3). For instance, growth arrest and DNA-damage-
inducible, alpha (GADD45A), an essential component of many
metabolic pathways that control proliferating cancer cells [43] had
relatively high expression levels in engrafted cells. B-cell CLL/
lymphoma 2 (BCL2) protein which was highly expressed in non-
engrafted cells has been previously shown to suppress the
expression of human GADD45A protein [44]. Whether over
expression of BCL2 in non-engrafted cells negatively regulates the
expression of GADD45A thereby promoting a loss of engraftment
potential requires closer examination. Similarly, expression of
thrombospondin1 (THBS1) which has a role in the activation of
MAPK [45], anti-apoptosis [46], and cell cycle arrest [47] was
upregulated in engrafted cells. THBS1 protein decreases the
secretion of IL2 [48], which, as noted above and in Figure 3, is
associated with non-engrafting cells. Integrin, alpha 2 (ITGA2 or
CD49B) which is involved in cell adhesion and cell-surface
mediated signaling [49] was upregulated in engrafted cells while
the androgen receptor (AR or dihydrotestosterone receptor) was
overexpressed in non-engrafting cells. Interestingly, 5alpha-
dihydrotestosterone has been previously shown to decrease the
expression of ITGA2 [50]. It would have been very interesting and
informative if we could have extended these analyses to cells in S/
G+M phases of cell cycle. Unfortunately, only a very small
percentage of UCB and MPB-derived CD34
+ cells are in S/
G2+M [4,6], making the isolation of sufficient numbers of these
cells extremely difficult.
These observations suggest that maintenance and loss of
engraftment potential may be controlled by an orchestrated
sequence of gene expression profiles that oscillate HSC between
engrafting and non-engrafting potential. It would be interesting to
closely examine whether these gene expression profiles are
modulated by the progression of cells through different phases of
cell cycle. Such associations between cell cycle status and a genetic
fingerprint that promotes engraftment may explain why position of
HSC in cell cycle is an important parameter in determining their
engraftment potential. Alternating status of engraftment potential
of HSC has been previously reported by Quesenberry and
colleagues [7,8,51,52,53]. It is important to stress here that
restriction of engraftment to cells in G0 may not be applicable to
unseparated BM cells. However, the necessity to use purified cells
for genomic and proteomic analyses, preclude the use of
unseparated cells for these studies.
We compared our 484 target genes identified by microarray
analysis to the published stem cell database where Ivanova et al.
[25] mapped mRNA expression profiles of hematopoietic stem
cells of various phenotypically defined hierarchical levels or
clusters including LT-HSC, ST-HSC, and early-intermediate-late
progenitors. Among the functionally annotated 341 genes
identified in our set, 57, which mapped to all clusters of
hematopoietic cells examined, were present in the database of
Ivanova et al. Hypothetical expression patterns used by Ivanova et
al., [25] for cluster assignment may be one of the reasons for our
target list matching to all clusters. It is important to note that when
we compared our target gene list to common genes expressed by
different types of stem cells (HSC, ESC, and NSC as per the
definition of Ivanova et al), 14 genes were common to both lists
and interestingly, all of them mapped to higher clusters of HSC
developmental hierarchy.
Using mass spectrometry based proteomic analysis we success-
fully identified 646 proteins from the same 18 groups of cells that
were subjected in parallel to microarray analysis. Analysis
strategies similar to those used with our microarray data revealed
that only 4 common proteins were differentially expressed in both
BM and MPB, and not changed in UCB. We consider this a huge
constraint of our proteomic analysis since compared to data from
microarrays. We were limited to the identification of a rather small
number of expressed proteins using currently available techniques.
Given the logistical difficulties involving the flow cytometric cell
sorting of highly purified phenotypically defined groups of cells,
and the decision not to mix samples, we were only able to use a
rather small number of sorted cells (2610
5 cells) for the proteomic
analysis of each sample. This may have contributed significantly to
why only few proteins were identified in our analysis. It is also
important to note that another possible reason for our inability to
identify a larger number of proteins is that cells in our samples are
mostly metabolically inactive thus limiting the proteome abun-
dance. The use of independent pooled samples with significantly
higher numbers of cells may have generated a more robust set of
proteomic data and showed a higher synergy between the
transcriptome and microarray analyses of these cells.
We found a poor correlation between microarray and
proteomic results. For instance, among the 62 differentially
expressed proteins between BM G0 and G1 cells (Table S5), only
10 matched to differentially expressed genes by ID matching
(ignoring hypothetical- putative proteins, that could not be
matched to microarray gene ID). Such discrepancies between
proteomic and microarray data were previously reported
[13,14,15,16]. For example, Gygi et al. detected a 20 fold-increase
Figure 3. Candidate genes were analyzed by Ingenuity
pathway analysis software. Upregulated genes in engrafted cells
(G0 cells of BM, MPB; G0 and G1 cells of UCB) and upregulated genes in
non-engrafted cells (G1 cells of BM and MPB) were put side by side and
direct and indirect relations between the two sets were drawn. Several
genes that are upregulated in non-engrafted cells have an inverse
function on the genes that are upregulated in engrafted cells or vice
versa. Genes represented with blue, green, and red arrow lines have
opposite functions.
doi:10.1371/journal.pone.0017498.g003
Genomic & Proteomic Analysis of Human CD34
+ Cells
PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e17498in protein expression for some genes that were unaltered at the
mRNA level by microarray analysis [16,54]. Clearly, a twofold
differential expression of genes may not necessarily result in a
twofold change in protein expression [55]. In addition, several
mRNA molecules are not translated and may act as transcription
regulators or may decay before protein is synthesized [56,57]
leading to a differential expression of genes, but not proteins.
Therefore, thresholds applied to identify differential expression of
genes and proteins may not reflect the in vivo status of transcription
and translation.
Our studies confirm what several investigators in this field have
suspected for a long time, namely that it is not the mitotic
quiescence of HSC per se that is responsible for the superior
functional capabilities of these cells but instead, the genomic status
associated with or resulting from their position in cell cycle. We
purposefully adopted an analysis strategy that stripped away
differences between UCB-derived G0 and G1 cells thus eliminat-
ing any genomic difference that may be attributed to the cell cycle
status of these functionally similar groups of cells. This approach
revealed the presence of non cell cycle related genes contributing
to the engrafting potential of putative HSC that matched genes
identified by other microarray analysis strategies [25]. Obviously,
our results cannot rule out that cell cycle related genes do play a
role in conferring functional prowess to mitotically inactive cells.
Another intriguing finding in these studies is the detection of genes
in one of the two fractions analyzed from each tissue capable of
modulating the expression of other genes expressed in the
opposing fraction. These data suggest that a Yin and Yang system
of gene expression patterns in HSC may exist allowing for the
oscillation of cells, perhaps in a cell cycle related fashion, between
engrafting and non-engrafting status thus generating a continuum
of functions from within what would otherwise appear as a
heterogeneous population of cells. This model of cell cycle related
stem cell function and the oscillation between possessing and losing
functional properties within the same cell population was
previously described experimentally [51] and proposed conceptu-
ally by several groups for adult [7,8,9,10] and embryonic cells
[58]. Interestingly, this model of stem cell flexibility allows for
more than one group of cells within a given hematopoietic tissue to
possess basic and essential stem cell properties when needed. Such
would be the case for fetal hematopoietic cells which engraft
regardless of their position in cell cycle probably because of the
high requirement for hematopoietic cells during development and
the continued migration of hematopoiesis from one hematopoietic
site to another during ontogeny.
Supporting Information
Figure S1 Phenotypic analysis of UCB and BM cell
isolated in G0 or G1 phases of cell cycle. Each group of
sorted cells was stained with the 10 hematopoietic markers listed
next to each row of histograms (FITC-conjugated) and analyzed
separately. Grey histogram denotes isotype control and green
histogram denotes test sample.
(TIF)
Table S1 The list of target genes identified by micro-
array analysis.
(XLS)
Table S2 Comparison of target genes with published
database. (A): Common genes found between microarray
identified target genes and published hematopoietic stem cell
database [25]. (B): Common genes found between the microarray
identified target genes and the stem cell genes that are conserved
and found common among HSC, ESC, and NSC.
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Table S3 The list of total proteins identified by liquid
chromatography - mass spectrometry (LC/MS).
(XLS)
Table S4 Variability charts of identified total proteins
differential expression, including unchanged proteins
expression. For each protein, a plot of the group mean protein
intensity levels on the log base 2 scale plus or minus the standard
error is shown. The standard error is computed from the statistical
model and is a measure of the precision of the mean.
(DOC)
Table S5 Differentially expressed proteins between G0
and G1 cells of BM, MPB, and UCB. (A): Differentially
expressed proteins between G0 and G1 cells of BM. (B):
Differentially expressed proteins between G0 and G1 cells of
MPB. (C): Differentially expressed proteins between G0 and G1
cells of UCB.
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